The US FDA has scheduled a Vaccine and Related Biological Products Advisory Committee (VRBPAC) meeting for Wednesday, November 16, 2016 to review the biologics license application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)], submitted by Dynavax Technologies Corporation (Dynavax) for immunization against infection caused by all known subtypes of hepatitis B virus in adults.

See the SAC Tracker report

Update: The FDA has cancelled this meeting.